Drug Trial Radar · NCT04801693
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food
Last checked: Nov 20, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
66
Actual
Start
May 26, 2021
Primary completion
Apr 25, 2022
Study completion Apr 25, 2022
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objectives of the single rising doses (SRD) trial part are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy male subjects following administration of single rising doses. The main objective of the food effect part is to investigate the influence of food on the relative bioavailability of BI 1819479.
Conditions
- Healthy
Interventions
BI 1819479Drug
BI 1819479
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with drug-related adverse eventsTime frame: Up to Day 36
- Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to Day 31
- Maximum measured concentration of the analyte in plasma (Cmax)Time frame: Up to Day 31
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CRS Clinical Research Services Mannheim GmbH
Mannheim, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.